About Adamas Pharma
Adamas Pharma is a Healthcare company based in Emeryville (United States) founded in 2002, and was acquired by Supernus Pharmaceuticals in October 2021. It operates as a pharmacokinetic profiles of approved drugs are enhanced for CNS therapeutics. Adamas Pharma has raised $68.03 million across 5 funding rounds from investors including Supernus Pharmaceuticals, HHS and Northgate Capital. The company has 142 employees. Its chief executive is Neil F. McFarlane. Adamas Pharma offers products and services including QELBREE. Its focus areas include Life Sciences, Neurology, Drugs and Neurodegenerative. Its legal entity is ADAMAS PHARMACEUTICALS, INC.
Company details
Founded in 2002 and based in Emeryville, United States, Adamas Pharma operates as a specialty pharmaceutical company in the central nervous system (CNS) sector. Approved drugs pharmacokinetic profiles are enhanced to develop novel therapeutics, including fixed-dose combinations. The lead candidate, ADS-5102 (amantadine HCl extended-release), is evaluated for levodopa-induced dyskinesia in Parkinsons disease and walking impairment symptoms in multiple sclerosis.
- Headquarters Emeryville, United States
- Employees 142
- Stage Acquired
- SectorsHealthcare
- Website adamaspharma.com
- Social LinkedIn
- Acquired by Supernus Pharmaceuticals (Oct 2021)
- Legal Name Adamas Pharmaceuticals, Inc.
- Total Equity Funding$68.03M (USD)
in 5 rounds
- Latest Funding Round$1.25M (USD), Grant
Jul 2012
- InvestorsSupernus Pharmaceuticals
& 5 more
- Employee Count142
- Acquired bySupernus Pharmaceuticals
(Oct 2021)
Products & Services of Adamas Pharma
Adamas Pharma offers a comprehensive portfolio of products and services, including QELBREE.
Drug for treating central nervous system disorders with prescribing guidelines.
Funding Insights of Adamas Pharma
Adamas Pharma has successfully raised a total of $68.03M across 5 strategic funding rounds. The most recent funding activity was a Grant round of $1.25 million completed in July 2012. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $68.03M
- Total Rounds 5
- Last Round Grant — $1.25M
- First Round $8.68M
(May 2005)
- Investors Count 5
All 5 funding rounds of Adamas Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2012 | $1.25M | Grant | – | – | |
| Aug 2009 | $40M | Series D | – | – | |
| Aug 2007 | $13.09M | Series C | – | – | – |
| Aug 2006 | $6.25M | Series C | – | – | – |
| May 2005 | $8.68M | Series B | – | – | – |
6 investors in total: 6 institutional.
Investors in Adamas Pharma
Adamas Pharma has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Supernus Pharmaceuticals, HHS and Northgate Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Mid-stage venture capital investments and support for tech entrepreneurs. | – | dagventures.com | - | |
Venture capital investments are managed in technology and healthcare sectors by this firm. | – | mdv.com | - | |
Northgate Capital is engaged in venture capital and private equity investments. | 2000 | northgate.com | San Francisco, United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - | |
Private investment services are offered by Calibrium for clients. | – | clbrm.com | Zürich, Switzerland | |
Specialty pharmaceutical products for CNS diseases are developed and commercialized. | 2005 | supernus.com | Rockville, United States |
Investor details for Adamas Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Adamas Pharma
301 people are tracked at Adamas Pharma (94 in leadership, 7 in board & advisors, 200 in team); the tracked headcount is 142.
| Name | Role | Group |
|---|---|---|
Neil F. McFarlane | CEO | Leadership |
Jack A. Khattar | President & CEO | Leadership |
Rose Lieberman | Associate Director, Clinical Development | Leadership |
Sarah Torres | Director, Marketing | Leadership |
Henry Anderson | Director, Digital Marketing & Omnichannel Operations | Leadership |
Steve Gabuzda | Regional Director - Great Lakes | Leadership |
Sarah Branning | Associate Director, Access Reimbursement Management | Leadership |
Tiffany Caçoilo | Director, Human Resources- HR Partners | Leadership |
Uzma Zafer | Senior Executive Assistant To Senior Vice President | Leadership |
Grace Jan | Director, Sales Operations And Corporate Events | Leadership |
Rigo C. | Vice President Of Commercial Operations | Leadership |
MacIej Gasior | Executive Director, Clinical Development | Leadership |
Jonathan Rubin | Chief Medical Officer & SVP, Research & Development | Leadership |
Gang Luo | Director, Preclinical DMPK & Pharmacology | Leadership |
Austin Eikenberry | Associate Director | Leadership |
Padmanabh P. Bhatt | SVP, Intellectual Property and Chief Scientific Officer | Leadership |
Ernane Souza | Associate Director, Translational PKPD And DMPK | Leadership |
Kisha Bethune | Senior Director Sales Effectiveness & Analytics | Leadership |
Sesilie Oehler | National Account Director- Commercial & Govt; National Sales Director - Federal Accounts | Leadership |
Chris March | Vice President Human Resources | Leadership |
281 more people are available in the full profile.
Complete people profiles for Adamas Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Adamas Pharma
5 dated milestones of Adamas Pharma across 19 years, from founding to its latest funding, stage changes and deals.
- Founded Adamas Pharma is founded.
- Funding First funding round of $8.7M.
- Funding Latest funding round, Grant, of $1.3M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Supernus Pharmaceuticals.
Web traffic of Adamas Pharma
Websites that share an audience with Adamas Pharma (adamaspharma.com).
Websites whose visitors overlap most with Adamas Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| neuropace.com | 100% | 27.7K | #1,078,249 | View details | |
| 1life.com | 100% | 2.1K | #5,669,324 | View details | |
| intersectent.com | 100% | – | – | View details |
Top companies in Neurology
10 companies that operate in the same segment as Adamas Pharma (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | 541 | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Adamas Pharma
Complete news archive for Adamas Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Adamas Pharma
Adamas Pharma was founded in 2002 and raised its 1st funding round 3 years after it was founded.
Adamas Pharma is headquartered in Emeryville, United States. It is registered at Emeryville, California, United States.
Neil F. McFarlane is the current CEO of Adamas Pharma.
Adamas Pharma is a funded company, having raised a total of $68.03M across 5 funding rounds to date. The company's 1st funding round was a Series B of $8.68M, raised on May 2005.
Adamas Pharma has 142 employees.
Founded in 2002 and based in Emeryville, United States, Adamas Pharma operates as a specialty pharmaceutical company in the central nervous system (CNS) sector. Approved drugs pharmacokinetic profiles are enhanced to develop novel therapeutics, including fixed-dose combinations. The lead candidate, ADS-5102 (amantadine HCl extended-release), is evaluated for levodopa-induced dyskinesia in Parkinsons disease and walking impairment symptoms in multiple sclerosis.
Adamas Pharma offers QELBREE.
Adamas Pharma has 6 investors. Key investors include Supernus Pharmaceuticals, HHS, Northgate Capital, Calibrium, and DAG Ventures.
Adamas Pharma operates through Adamas Pharmaceuticals, Inc..
Yes. Adamas Pharma was acquired by Supernus Pharmaceuticals in October 2021.